Introduction

Although advances in immunosuppressive therapy have dramatically improved short-term outcomes following renal transplantation, long-term graft survival has not improved to the same extent. The nephrotoxicity of calcineurin inhibitors (CNIs) contributes to chronic graft dysfunction (1), and since renal function at 12 months posttransplant potentially predicts long-term graft function (2-4), optimizing renal function is critical. Thus, a key challenge is to develop immunosuppressive strategies that allow early CNI minimization or elimination and lead to the reduction of CNI-related adverse events (AEs) while maintaining current low acute-rejection rates.
Everolimus is a mammalian target of rapamycin (mTOR) inhibitor/proliferation-signal inhibitor (PSI) with potent immunosuppressive and antiproliferative effects
, and is highly effective in preventing acute rejection in renaltransplant recipients (6) (7) (8) (9) . Although, in initial trials, everolimus plus standard-exposure CsA (ST-CsA) demonstrated equivalent efficacy to MMF plus ST-CsA in de novo renal-transplant recipients, renal function was reduced in everolimus-treated patients (6, 9, 10) . However, Phase III studies have demonstrated that everolimus allows early CNI minimization while maintaining good efficacy and renal function (7) . Various everolimus and CsA dosing regimens have been assessed (11) (12) (13) (14) , culminating 
Materials and Methods
Study design
This study was a Phase IIIb, 24- 
Patients
Patients aged 18-70 years undergoing primary kidney transplantation were eligible. Key exclusion criteria included, kidneys donated after cardiac death or with a cold ischemia time >40 hours; donor age >65 years; recipients of multiorgan-, ABO-incompatible-, positive T-cell cross-match-or HLAidentical living-related-donor transplants; or most recent anti-HLA Class I panel-reactive antibodies (PRA) >20% by a CDC (complement-dependent cytotoxicity)-based assay or >50% by flow cytometry or ELISA.
Immunosuppressive therapy
Eligible patients received basiliximab (20 mg) Tedesco Silva Jr. et al. Everolimus Plus Reduced-Exposure CsA (19) (20) (21) . Building upon previous data (8, 12, 13, 22) The overall safety profile of everolimus was similar to that seen in previous studies (8, (11) (12) (13) (14) ; approximately 50 000 patient-years of everolimus experience now exists (24 
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